Current snakebite antivenoms are based on polyclonal animal-derived antibodies, which can neutralize snake venom toxins in envenomed victims, but which are also associated with adverse reactions. Therefore, several efforts within antivenom research aim to explore the utility of recombinant monoclonal antibodies, such as human immunoglobulin G (IgG) antibodies, which are routinely used in the clinic for other indications. In this study, the feasibility of using tobacco plants as bioreactors for expressing full-length human monoclonal IgG antibodies against snake toxins was investigated. We show that the plant-produced antibodies perform similarly to their mammalian cell-expressed equivalents in terms of in vitro antigen binding. Complete neutralization was achieved by both the plant and mammalian cell-produced anti-α-cobratoxin antibody. The feasibility of using plant-based expression systems may potentially make it easier for laboratories in resource-poor settings to work with human monoclonal IgG antibodies. Display omitted •Therapeutic antibodies are typically expressed in mammalian cell systems and are inaccessible to resource-poor regions.•Alternative expression systems may be attractive to manufacturers of recombinant antivenoms in resource-poor regions.•Toxin-targeting antibodies were expressed in both tobacco plants and mammalian cells.•Plant and mammalian cell-produced antibodies showed similar antigen binding.•Complete in vitro neutralization was achieved by both the plant and mammalian cell-produced anti-α-cobratoxin antibodies.